51 citations
,
October 2012 in “International Journal of Immunopathology and Pharmacology” Finasteride works better than Serenoa repens for male hair loss.
2 citations
,
October 2022 in “Skin appendage disorders” Activated and non-activated PRP are equally safe and effective for treating alopecia areata.
2 citations
,
March 2025 in “International Journal of Dermatology” Tralokinumab successfully treated alopecia areata in a patient with atopic dermatitis.
June 2024 in “Dermatology and Therapy” Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.
6 citations
,
October 2012 in “Pediatrics” Serenoa repens (saw palmetto) may cause side effects like hot flashes in children and needs more research for safety in pediatric use.
December 2023 in “Journal of Medicinal Chemistry” A new topical treatment for hair loss shows strong hair growth effects with low toxicity.
April 2026 in “Clinical and Translational Science” Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
May 2025 in “Russian Journal of Allergy” Combining antihistamines with topical treatment improves hair regrowth in alopecia areata.
December 2025 in “PubMed” Baricitinib is effective and safe for treating severe alopecia areata.
4 citations
,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
3 citations
,
March 2023 in “Journal of Medical Economics” Middle-aged patients, those in the Northeast, with comprehensive insurance, extensive hair loss, or additional health issues, and young or older females face higher alopecia areata medical costs.
7 citations
,
August 2023 in “Journal of the American Academy of Dermatology” JAK inhibitors offer new hope for treating severe alopecia areata.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” The study developed a mouse model for Alopecia Areata that responds to treatment, useful for future research.
128 citations
,
February 2016 in “British Journal of Dermatology” Alopecia areata significantly lowers the quality of life, especially in emotional and mental health aspects.
December 1977 in “Archives of Dermatology” Hair regrowth in alopecia areata is common, but recurrences happen frequently.
February 2026 in “International Journal of Dermatology” Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
36 citations
,
November 2020 in “Journal of The European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
44 citations
,
October 2009 in “Journal of the American Academy of Dermatology” Topical bexarotene 1% gel might help regrow hair in alopecia areata and is generally safe.
January 2012 in “The Year book of dermatology” Many treatments for alopecia areata have inconsistent results; for under 10s, use minoxidil with a corticosteroid, and for over 10s, add ILC and consider diphenylcyclopropenone for widespread cases.
February 2026 in “Biomedicines” Off-label treatments are heavily used for alopecia areata due to limited approved options.
95 citations
,
July 2016 in “Journal of The American Academy of Dermatology” People with alopecia areata, a skin disease, generally have a poor quality of life, especially if more of their scalp is affected.
53 citations
,
January 2014 in “Journal of Cutaneous and Aesthetic Surgery” Microneedling combined with triamcinolone can safely stimulate faster hair regrowth in people with Alopecia Areata.
44 citations
,
February 2015 in “Journal of the American Academy of Dermatology” Combining diphenylcyclopropenone with anthralin is more effective for hair regrowth in alopecia areata than using diphenylcyclopropenone alone, but may cause more side effects.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
4 citations
,
January 2015 in “Pharmacology” Serenoa repens may cause early puberty and should be used cautiously in children.
July 2024 in “Journal of Investigative Dermatology” CD8+ T cells expand significantly in alopecia areata, suggesting new treatment targets.
September 2022 in “Hair transplant forum international” JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.